Selected data models

You must log in to select data models for download or further analysis.

4 Search results.
Relevance Rating New first Old first

Fluticasone Furoate GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma NCT01165138 - Date of Visit/ Assessment, Vital signs, Candidiasis Examination, Inhaler Ease Of Use Assessment,Device Use Assessment, Subject Withdrawal Status, Electronically transferred lab data, Liver Events Assessment - Visit 5

- 11/23/18 - 1 form, 8 itemgroups, 21 items, 1 language
Itemgroups: Date of Visit/ Assessment, Vital signs, Candidiasis Examination , Inhaler Ease Of Use Assessment, Device Use Assessment , Subject Withdrawal Status , Electronically transferred lab data , Liver Events Assessment
Study ID: 106827 Clinical Study ID: HZA106827 Study Title: HZA106827:A randomised, double-blind, placebo-controlled (with rescue medication), parallel group multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma in adults and adolescents Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01165138 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: fluticasone furoate/vilanterol Trade Name: Allermist,Veramyst,Avamys; Relvar Study Indication: Asthma

Fluticasone Furoate GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma NCT01165138 - Date of Visit/ Assessment, Vital signs, Candidiasis Examination, Device Use Assessment, Subject Withdrawal Status, Electronically transferred lab data, Liver Events Assessment - Visit 4

- 11/23/18 - 1 form, 7 itemgroups, 19 items, 1 language
Itemgroups: Date of Visit/ Assessment, Vital signs, Candidiasis Examination , Device Use Assessment , Subject Withdrawal Status , Electronically transferred lab data , Liver Events Assessment
Study ID: 106827 Clinical Study ID: HZA106827 Study Title: HZA106827:A randomised, double-blind, placebo-controlled (with rescue medication), parallel group multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma in adults and adolescents Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01165138 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: fluticasone furoate/vilanterol Trade Name: Allermist,Veramyst,Avamys; Relvar Study Indication: Asthma

Fluticasone Furoate GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma NCT01165138 - Date of Vsit/ Assessment, Investigational Product, Vital signs, Candidiasis Examination, Electronically transferred lab data, Liver Events Assessment , PK Sample- Pre Dose, PK Sample, Subject Withdrawal Status - Visit 7

- 11/23/18 - 1 form, 10 itemgroups, 27 items, 1 language
Itemgroups: Date of Visit/ Assessment, Investigational Product, Vital signs, Candidiasis Examination , Electronically transferred lab data , Liver Events Assessment , PK Sample- Pre Dose, PK Sample - 15 Minutes Post- Dose, PK Sample - 1.5 Hours Post- Dose , Subject Withdrawal Status
Study ID: 106827 Clinical Study ID: HZA106827 Study Title: HZA106827:A randomised, double-blind, placebo-controlled (with rescue medication), parallel group multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma in adults and adolescents Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01165138 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: fluticasone furoate/vilanterol Trade Name: Allermist,Veramyst,Avamys; Relvar Study Indication: Asthma

Fluticasone Furoate GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma NCT01165138 - Medical Conditions, Family History, Disease Duration, Vital Signs, Candidiasis Examination, Electronically Transferred Lab Data - Screening

- 11/21/18 - 1 form, 11 itemgroups, 34 items, 1 language
Itemgroups: Medical Conditions - Cardiac Disorders, Medical Conditions - Endocrine Disorders, Medical Conditions - Eye Disorders, Medical Conditions - Vascular Disorders, Medical Conditions - Metabolism and Nutrition Disorders, Medical Conditions - Infections and Infestations, Family History, Disease Duration, Vital Signs, Candidiasis Examination, Electronically transferred lab data
Study ID: 106827 Clinical Study ID: HZA106827 Study Title: HZA106827:A randomised, double-blind, placebo-controlled (with rescue medication), parallel group multicentre study of Fluticasone Furoate/GW642444 Inhalation Powder and Fluticasone Furoate Inhalation Powder alone in the treatment of persistent asthma in adults and adolescents Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01165138 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: fluticasone furoate/vilanterol Trade Name: Allermist,Veramyst,Avamys; Relvar Study Indication: Asthma

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial